Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001157524
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name Phone

E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

001-39655

75 State Street
Suite 100

Address of Issuer

Boston

MASSACHUSETTS

02109

Phone 45-70-70-52-10

Name of Person for Whose Account the Securities are To Be Sold

The Biotech Growth Trust PLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	SOCILAITIOC
Common Stock	Bank of America One Bryant Park New York NY 10036	119679	69414.00	27112697	08/30/2023	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *
	_	Transaction			Acquired	Acquired		

Whom a Acquired Gift?

Common Stock 09/25/2020 Private Placement Issuer

119679

09/25/2020 Cash

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Securities Sale Sold	Gross Proceeds
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/13/2023 14700	35280.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/25/2023 8100	23652.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/31/2023 40600	121800.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/15/2023 58320	43740.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/21/2023 4809	2998.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/22/2023 2978	1846.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/23/2023 6199	3916.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/24/2023 4705	2903.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/25/2023 2712	1629.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/28/2023 2158	1203.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/29/2023 4111	2360.00

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

144: Remarks and Signature

Remarks OrbiMed Capital LLC is the portfolio manager of The Biotech Growth Trust PLC.

Date of

08/30/2023

Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Capital LLC, portfolio manager of The Biotech Growth Trust PLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)